Mann K, Kiefer F, Spanagel R, Littleton J (July 2008). “Acamprosate: recent findings and future research directions”. Alcohol. Clin. Exp. Res.32 (7): 1105–10. doi:10.1111/j.1530-0277.2008.00690.x. PMID18540918.
Tsai, G; Coyle, JT (1998). “The role of glutamatergic neurotransmission in the pathophysiology of alcoholism”. Annual review of medicine49: 173–84. doi:10.1146/annurev.med.49.1.173. PMID9509257.
Mayer, S; Harris, BR; Gibson, DA; Blanchard, JA; Prendergast, MA; Holley, RC; Littleton, J (2002). “Acamprosate, MK-801, and ifenprodil inhibit neurotoxicity and calcium entry induced by ethanol withdrawal in organotypic slice cultures from neonatal rat hippocampus”. Alcoholism, clinical and experimental research26 (10): 1468–78. doi:10.1097/01.ALC.0000033261.14548.D2. PMID12394279.
Al Qatari, M; Khan, S; Harris, B; Littleton, J (2001). “Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain”. Alcoholism, clinical and experimental research25 (9): 1276–83. doi:10.1111/j.1530-0277.2001.tb02348.x. PMID11584146.
Adde-Michel, C; Hennebert O, Laudenbach V, Marret S, Leroux P (2005). “Effect of acamprosate on neonatal excitotoxic cortical lesions in in utero alcohol-exposed hamsters”. Neuroscience Letters374 (2): 109–112. doi:10.1016/j.neulet.2004.10.037. PMID15644274.
Mason, BJ; Goodman AM, Chabac S, Lehert P (2006). “Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation”. J Psychiatr Res40 (5): 383–393. doi:10.1016/j.jpsychires.2006.02.002. PMID16546214.
Feeney, GF; Connor JP, Young RM, Tucker J, McPherson A (2006). “Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: A single centre's experience with pharmacotherapy”. Alcohol Alcohol41 (3): 321–327. doi:10.1093/alcalc/agl007. PMID16467406.
Mason, BJ (2001). “Treatment of alcohol-dependent outpatients with acamprosate: a clinical review.”. The Journal of clinical psychiatry62 Suppl 20: 42–8. PMID11584875.
Tsai, G; Coyle, JT (1998). “The role of glutamatergic neurotransmission in the pathophysiology of alcoholism”. Annual review of medicine49: 173–84. doi:10.1146/annurev.med.49.1.173. PMID9509257.
Tsai, GE; Ragan, P; Chang, R; Chen, S; Linnoila, VM; Coyle, JT (1998). “Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal”. The American Journal of Psychiatry155 (6): 726–32. PMID9619143.
De Witte, P; Littleton, J; Parot, P; Koob, G (2005). “Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action”. CNS Drugs19 (6): 517–37. PMID15963001.
Mayer, S; Harris, BR; Gibson, DA; Blanchard, JA; Prendergast, MA; Holley, RC; Littleton, J (2002). “Acamprosate, MK-801, and ifenprodil inhibit neurotoxicity and calcium entry induced by ethanol withdrawal in organotypic slice cultures from neonatal rat hippocampus”. Alcoholism, clinical and experimental research26 (10): 1468–78. doi:10.1097/01.ALC.0000033261.14548.D2. PMID12394279.
Al Qatari, M; Khan, S; Harris, B; Littleton, J (2001). “Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain”. Alcoholism, clinical and experimental research25 (9): 1276–83. doi:10.1111/j.1530-0277.2001.tb02348.x. PMID11584146.
Engelhard, K; Werner C, Lu H, Mollenberg O, Zieglgansberger W, Kochs E (2006). “The neuroprotective effect of the glutamate antagonist acamprosate following experimental cerebral ischemia. A study with the lipid peroxidase inhibitor u-101033e”. Anaesthesist49 (9): 816–821. PMID11076270.
Adde-Michel, C; Hennebert O, Laudenbach V, Marret S, Leroux P (2005). “Effect of acamprosate on neonatal excitotoxic cortical lesions in in utero alcohol-exposed hamsters”. Neuroscience Letters374 (2): 109–112. doi:10.1016/j.neulet.2004.10.037. PMID15644274.
Mason, BJ; Goodman AM, Chabac S, Lehert P (2006). “Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation”. J Psychiatr Res40 (5): 383–393. doi:10.1016/j.jpsychires.2006.02.002. PMID16546214.
Feeney, GF; Connor JP, Young RM, Tucker J, McPherson A (2006). “Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: A single centre's experience with pharmacotherapy”. Alcohol Alcohol41 (3): 321–327. doi:10.1093/alcalc/agl007. PMID16467406.
